Analysts Conflicted on These Healthcare Names: Moleculin Biotech (MBRX) and Insulet Corp (PODD)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moleculin Biotech (MBRX) and Insulet Corp (PODD).

Moleculin Biotech (MBRX)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech, with a price target of $3. The company’s shares opened today at $1.39.

McCarthy commented:

“Moleculin reported YE18 with a net loss of ($11.9M) and ended the period with ~$7M in cash, runway into 3Q19. The company also has $18M remaining on an equity line. Management continued to execute in 2018 and position its two lead programs (Annamycin and the STAT3 candidates) to reach data points in 2019, which should if positive unlock value for MBRX shareholders. Important in our view is to focus on why these assets are differentiated in the oncology space and how that could translate into a higher probability of success in the clinic. We review in more detail below.”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -1.5% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.

Currently, the analyst consensus on Moleculin Biotech is a Moderate Buy with an average price target of $5.50.

See today’s analyst top recommended stocks >>

Insulet Corp (PODD)

Oppenheimer analyst Steven Lichtman maintained a Hold rating on Insulet Corp today and set a price target of $100. The company’s shares opened today at $93.42.

Lichtman noted:

“Insulet’s 4Q18 sales of $164.9M (+24%) outpaced our/Street’s $162.7M/$162.4M ests, led by higher US performance. Gross margin of 66.9% was about in line with our 67.2%E. Opex leverage was solid and led to higher than expected EPS of $0.16 vs. our/Street’s $0.09/$0.07E. FY19 sales guidance of $662-687M (+17-22% yoy) compares to the Street’s $690M view. Initial US and Drug Delivery guidance lagged our estimate, while International is ahead. Management highlighted full release of DASH (around 1Q-end), HORIZON approval that remains on track for 2H20E, continued pharmacy-channel development (expected to increase in ’19 on launch of DASH and on payer discussions), and increasing coverage from Medicare/Medicaid. Below the top line, management highlighted the expected gross margin benefits of its soon to be operational new manufacturing facility.”

According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.5% and a 50.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

Currently, the analyst consensus on Insulet Corp is a Moderate Buy with an average price target of $102.80, a 10.0% upside from current levels. In a report released today, BTIG also maintained a Hold rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.